A Phase 4 interventional study of Mirabegron and Placebo in Overactive Bladder and Parkinson Disease, sponsored by Seoul National University Hospital. Status unknown at 5 sites in Korea, Republic of. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-01-30.
Sponsored by Seoul National University Hospital · Phase 4, Interventional, and Treatment
Among 62 studies testing mirabegron in Urinary Bladder, Overactive — 9 open to participants now, 9 under way, 3 of them phase 3. mirabegron · Urinary Bladder, Overactive.
Among the 62 studies testing mirabegron in Urinary Bladder, Overactive, this one is the 38th largest by planned enrollment, is one of 4 that started in 2017, is one of 25 in phase 4, and was the 41st registered.
858 studies on the registry are indexed under Urinary Bladder, Overactive; 126 are open to participants now.
Browse Urinary Bladder, Overactive studies →9 of the 62 studies testing mirabegron in Urinary Bladder, Overactive are open now, in 4 countries. Recruiting first, the newest first:
University of Aarhus · Sites in Denmark
Ages 5–14
Far Eastern Memorial Hospital · Sites in Taiwan
Ages 20+ · Women only
University of California, San Francisco · Sites in United States
Ages 60+ · Women only · Healthy volunteers
Walter Reed National Military Medical Center · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Mackay Memorial Hospital · Sites in Taiwan
Ages 40–90 · Women only
By country, each count listing its studies:
mirabegron: first FDA approval 2012 (MYRBETRIQ), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 73 Urinary Bladder, Overactive studies recruiting now, 44 (60%) set no upper age limit and 15 (21%) stop at 75 or younger; 6 take children under 18; 8 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 8 · Phase 3 19 · Phase 4 25
First in 2004; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 144 is above the median of 70 across 649 interventional studies indexed under Urinary Bladder, Overactive.
Median enrollment 190 across the 62 interventional studies. Of the 44 that completed or were terminated, 24 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 62 have an industry lead sponsor. The 10 most frequent:
Seoul National University Hospital is the lead sponsor of 1,900 studies on the registry; 274 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
Seoul National University Hospital has 7 studies filed under Urinary Bladder, Overactive — fewer than ten, so there is no comparison to draw.
3 of the studies testing mirabegron in Urinary Bladder, Overactive that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06551246Phase 3University of AarhusEfficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry) | 2027-10-01 |
| NCT05221021Walter Reed National Military Medical CenterVaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome | 2026-12-30 |
| NCT05362292University of California, San FranciscoTReating Incontinence for Underlying Mental and Physical Health | 2027-05-02 |
Add all 3 to your calendar (.ics) → With an account.
Among the 62 studies testing mirabegron in Urinary Bladder, Overactive, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see the study drug, Mirabegron, is safe and effective in treating symptoms of Overactive Bladder in patients with Parkinson's disease.
This study is a randomized 1:1 placebo-controlled 12-week study of Mirabegron in 144 Parkinson's subjects the age of 40 to 80 with overactive bladder. Active drug will be Mirabegron 50mg daily. Subjects will be enrolled based on response to an overactive bladder questionnaire at visit 1. Enrolled subjects will have 3 study visits to the clinic as well as 1 phone visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1:1 randomization to receive Mirabegron 50mg daily or placebo at visit 2. At visit 4 all subjects will receive Mirabegron 50mg.
Drug: Mirabegron
1:1 randomization to receive Mirabegron 50mg daily or placebo at visit 2. At visit 4 all subjects will receive Mirabegron 50mg.
Drug: Placebo
Mirabegron 50mg po daily for 12 weeks to Active Comparator group, and 4 weeks(from visit 4 to visit 5) to Placebo comparator group.
Also known as: Betmiga PR 50mg
Placebo po daily for 8 weeks to Placebo comparator group.
Also known as: sugar pill
Change in the total score of Overactive Bladder Symptom Scale(OABSS)
Change in the total score of Overactive Bladder Symptom Scale(OABSS) from baseline(Visit 2) to Visit 4
Time frame: Baseline(Visit 2 : 0 week), Visit 3(3-5 weeks post Visit 2), Visit 4(6-10 weeks post Visit 2), Visit 5(10-14 weeks post Visit 2)
Change in the total score of OABSS(Overactive Bladder Symptom Scale)
Change in the total score of OABSS, Visit 3, Visit 4 and Visit 5
Time frame: Baseline(Visit 2 : 0 week), Visit 3(3-5 weeks post Visit 2), Visit 4(6-10 weeks post Visit 2), Visit 5(10-14 weeks post Visit 2)
Change in the total score of IPSS(International Prostate Symptom Score)
Change in the total score of IPSS and bothersome score, Visit 3, Visit 4 and Visit 5
Time frame: Baseline(Visit 2 : 0 week), Visit 3(3-5 weeks post Visit 2), Visit 4(6-10 weeks post Visit 2), Visit 5(10-14 weeks post Visit 2)
Change in the total score of OAB-q short form
Change in the total score of OAB-q short form,Visit 3, Visit 4 and Visit 5
Time frame: Baseline(Visit 2 : 0 week), Visit 3(3-5 weeks post Visit 2), Visit 4(6-10 weeks post Visit 2), Visit 5(10-14 weeks post Visit 2)
Change in the total score of PPBC(Patient Perception of Bladder Condition)
Change in the total score of PPBC, Visit 3, Visit 4 and Visit 5
Time frame: Baseline(Visit 2 : 0 week), Visit 3(3-5 weeks post Visit 2), Visit 4(6-10 weeks post Visit 2), Visit 5(10-14 weeks post Visit 2)
Change in the total score of TSQ (Treatment Satisfaction Questionnaire)
Change in the total score of TSQ, Visit 3, Visit 4 and Visit 5
Time frame: Baseline(Visit 2 : 0 week), Visit 3(3-5 weeks post Visit 2), Visit 4(6-10 weeks post Visit 2), Visit 5(10-14 weeks post Visit 2)
Change in the total score of GRA (Global Response Assessment)
Change in the total score of GRA, Visit 3, Visit 4 and Visit 5
Time frame: Baseline(Visit 2 : 0 week), Visit 3(3-5 weeks post Visit 2), Visit 4(6-10 weeks post Visit 2), Visit 5(10-14 weeks post Visit 2)
Change in the score of BSW (Benefit, Satisfaction and Willingness to Continue Questions)
Change in the score of BSW, Visit 4 and Visit 5
Time frame: Baseline(Visit 2 : 0 week), Visit 3(3-5 weeks post Visit 2), Visit 4(6-10 weeks post Visit 2), Visit 5(10-14 weeks post Visit 2)
Change in the Mean Frequent Urination
Change in the Mean Frequent Urination, Visit 3 and Visit 4
Time frame: Baseline(Visit 2 : 0 week), Visit 3(3-5 weeks post Visit 2), Visit 4(6-10 weeks post Visit 2), Visit 5(10-14 weeks post Visit 2)
Change in the Mean number of Urinary urgency
Change in the Mean number of Urinary urgency, Visit 3 and Visit 4
Time frame: Baseline(Visit 2 : 0 week), Visit 3(3-5 weeks post Visit 2), Visit 4(6-10 weeks post Visit 2), Visit 5(10-14 weeks post Visit 2)
Change in the Mean number of Urinary incontinence
Change in the Mean number of Urinary incontinence, Visit 3 and Visit 4
Time frame: Baseline(Visit 2 : 0 week), Visit 3(3-5 weeks post Visit 2), Visit 4(6-10 weeks post Visit 2), Visit 5(10-14 weeks post Visit 2)
Started Jul 2017 (actual). Primary completion is estimated for Jul 2018, 11 months after the start.
Of 42 non-industry phase 4 interventional studies under Urinary Bladder, Overactive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 51. This study's planned 11 months is below that.
Counting every sponsor, half of 54 studies reached it within 23 months; a quarter within 15 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirabegron
Seoul National University Hospital →